Synovial Sarcoma Treatment Market Top Key Players, Growth, Competitive Landscape and Forecast till 2026
Synovial sarcoma
consists of abnormal growth of soft-tissue. Synovial sarcoma is a
rare type of cancer and is more prevalent in teenagers and young
adults. Synovial sarcoma is highly metastatic and spreads to other
places, in almost 50% of the cases and lungs are the common site for
metastasis to occur. The cause behind occurrence of synovial sarcoma
have not yet been established, however, it is found to be associated
with abnormality in chromosome X and chromosome 18 in tumor cells.
Depending on the type of cells involved, it is classified into
Monophasic and Biphasic, and poorly differentiated synovial sarcoma.
Diagnosis of the synovial sarcoma involves imaging of the affected
area, biopsy, genetic testing, and bone scans. Treatment of the
synovial sarcoma involves a few approaches ranging from medication to
surgery depending on the condition of the patient.
For instance,
surgery is considered if the tumor has clear margins and can be
removed alongside healthy tissue. If a surgery is not possible then
chemotherapy is opted which can kill cancerous as well as healthy
cells. Generally used chemotherapy drugs include ifofsamide,
doxorubicin, and other drugs include dacarbazine, epirubicin,
temozolomide, docetaxel, and gemcitabine. Moreover, radiotherapy may
also be used alongside chemotherapy or as a standalone therapy. Some
other therapies include angiogenesis inhibitors, which can prevent
growth of tumor, and biological therapies to boost patient’s
immunity system to fight against cancer. The treatment options highly
depend on individual condition of the patients, as there is no
standard treatment for it.
Request For
Sample Copy Of This Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/1571
Synovial
Sarcoma Treatment Market Drivers
According to
American Cancer Society estimates, the incidence of synovial sarcoma
in the U.S. for 2018 is expected to be 13,040 patients out of which
7,370 in males and 5,670 in females. Extensive research &
development in this field for the development of innovative therapies
for the treatment of synovial sarcoma is expected to boost the global
synovial sarcoma treatment market growth over the forecast period.
For instance, organizations such as Accuronix Therapeutics, Advenchen
Laboratories, LLC, Immune Design, Cue Biopharma, and others are
working on research and development of novel immunotherapy candidates
for the treatment of synovial sarcoma. Accuronix Therapeutics has
ACXT-3102, a small molecule drug conjugate, in preclinical
development for treatment of synovial sarcoma and other cancers.
Advanchen Laboratories has AL3818 (anlotinib) in Phase 3 clinical
trials for the treatment of synovial sarcoma (SS), and other
indications. Moreover, Immune Design has an antigen-specific prime
boost CMB305 in Phase 2 clinical trials for synovial sarcoma. Cue
Biopharma is working on CUE-102, a potential treatment for melanoma,
synovial sarcoma, prostate, and head and neck cancers.
Adaptimmune
Therapeutics received T-Cell therapy breakthrough designation by the
U.S. Food & Drug Administration (FDA) for its NY-ESO-1 T-cell
therapy in 2016. Immunocore, a U.K. based biotechnology company is
working on ImmTAC (Immune mobilizing monoclonal TCRs), which has
potential applications in various cancers including synovial sarcoma.
Furthermore, research on novel vaccines for the treatment of synovial
sarcoma is also underway, which could increase the treatment options
for synovial sarcoma. These factors are expected to boost growth of
the synovial sarcoma treatment market over the forecast period.
However, the side
effects associated with cancer treatment, high costs, and uncertainty
of the results of clinical trials is expected to affect the growth of
the market over the forecast period.
Synovial
Sarcoma Treatment Market Regional Insights
North America is
expected to witness significant growth over the forecast period due
to research and development, and high prevalence of the synovial
sarcoma. Immunotherapy is a popular treatment in the region, wherein,
application of immunotherapies such as checkpoint-inhibitors and
adoptive T cell therapy is being researched for the treatment of
synovial sarcoma. Another approach that is being studied, is the
combination therapy including two or more immunotherapy candidates,
which have shown potential effects in the synovial sarcoma treatment.
For instance, positive results of phase 2 studies of the combination
of Axitinib and Pembrolizumab in the treatment of advanced alveolar
soft part sarcoma and other soft tissue sarcomas were presented at
Connective Tissue Oncology Society Annual Meeting in 2017. Moreover,
Europe region is expected to witness high growth, owing to presence
of innovative biotech companies such as Immunocore, which are
actively involved in research and development of targeted therapies
such as ImmTAC.
Key players
operating in Synovial Sarcoma Treatment Market include Pfizer, Inc.,
Eli Lilly and Company, Genentech USA, F. Hoffmann-La Roche Ltd,
Johnson & Johnson, GlaxoSmithKline, Bristol-Myers Squibb, Teva
Pharmaceuticals, and Celgene Corporation among others.
Synovial
Sarcoma Treatment Market Taxonomy-
The global synovial
sarcoma treatment market is segmented on the basis of treatment type,
end user, and geography.
By Treatment
Type-
-
Chemotherapy
-
Anti-Angiogenesis Drugs
-
Radiotherapy
-
Others
By End User-
-
Hospitals
-
Oncology Centers
-
Others
Click
To Read More On Synovial
Sarcoma Treatment Market
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Comments
Post a Comment